Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FreshBurst Listerine protocol

This article was originally published in The Tan Sheet

Executive Summary

Pfizer proposes six-month, multi-center gingivitis study of 340 subjects at three clinical sites in Canada, Florida and Ohio for FreshBurst Listerine with Fluoride in Oct. 14 letter to FDA. Each center will have a principal investigator, who also may function as the site's clinical examiner. Pfizer originally had suggested a single-center study, which FDA opposed at an Aug. 27 feedback meeting (1"The Tan Sheet" Sept. 2, 2002, p. 14). Pfizer also agrees with FDA's suggestion to reduce the number of exclusion criteria. Pregnant women, diabetics, individuals with partial dentures or oral piercings are included under modified protocol, while those with "history of significant adverse events following use of oral hygiene products," "history of serious medical conditions" or alcoholism are excluded...

You may also be interested in...

FreshBurst Listerine protocol

FDA approves Pfizer's proposed six-month, multi-center, 340-person gingivitis study in recent letter, noting if the trial determines "Listerine with fluoride is as effective as Listerine in reducing gingivitis and plaque," agency likely will grant the sodium fluoride/essential oils combination monograph status. FDA says it "will explore regulatory mechanisms for interim marketing under the OTC drug monograph procedures at [that] time." Pfizer modified its study proposal in October after an FDA feedback meeting (1"The Tan Sheet" Nov. 18, 2002, In Brief)...

FreshBurst Listerine Study Must Exhibit 20% Gingivitis Reduction – FDA

A six-month study of FreshBurst Listerine with Fluoride will need to show "a 20% reduction in gingivitis" over the control to receive agency approval, FDA told Pfizer execs at an Aug. 27 meeting

Moderna Stands Alone With Single-Antigen Approach To COVID-19 Vaccine

Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts